Olema Pharmaceuticals shares are trading higher in possible sympathy with Radius Health, which reported positive results from its EMERALD Phase 3 study evaluating elacestrant. Olema is developing an estrogen receptor antagonist.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!